Jingji Wang

Dr. Jingji Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
SYShao-Jie Yang
Shao-Jie Yang
JWJingji Wang
Jingji Wang
PCPing Cheng
Ping Cheng
LCLi-Xia Chen
Li-Xia Chen
JHJia-Min Hu
Jia-Min Hu
GZGuoqi Zhu
Guoqi Zhu
Ginseng has been used in China as a superior medicinal material for thousands of years that can nourish the five internal organs, calm the mind and benefit wisdom. Due to its anti-inflammatory, antioxidant and neuroprotective activities, one of the active components of ginseng, ginsenoside Rg1, has been extensively investigated in the remedy of brain disorders, especially dementia and depression. In this review, we summarized the research progress on the action mechanisms of Rg1 ameliorating depression-like behaviors, including inhibition of hyperfunction of hypothalamic-pituitary-adrenal (HPA) axis, regulation of synaptic plasticity and gut flora. Rg1 may alleviate Alzheimer’s disease in the early phase, as well as in the middle-late phases through repairing dendrite, axon and microglia- and astrocyte-related inflammations. We also proposed that Rg1 could regulate memory state (the imbalance of working and aversive memory) caused by distinct stimuli. These laboratory studies would further the clinical trials on Rg1. From the prospective of drug development, we discussed the limitations of the present investigations and proposed our ideas to increase permeability and bioavailability of Rg1. Taken together, Rg1 has the potential to treat neuropsychiatric disorders, but a future in-depth investigation of the mechanisms is still required. In addition, drug development will benefit from the clinical trials in one specific neuropsychiatric disorder.

24 July 2024 in Cellular Signalling
Verified
Journal Article
Closed access
DCDaokang Chen
Daokang Chen
JWJingji Wang
Jingji Wang
JCJian Cao
Jian Cao
GZGuoqi Zhu
Guoqi Zhu

3 December 2021 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
FSFengming Shen
Fengming Shen
JWJuan Wang
Juan Wang
FGFeng Gao
Feng Gao
JWJingji Wang
Jingji Wang
GZGuoqi Zhu
Guoqi Zhu
This study is aimed at investigating the potential roles of G protein-coupled estrogen receptor 1 (GPER, also known as GPR30) in the preventive effect of ginsenoside Rg1 against cognitive impairment and hippocampal cell apoptosis in experimental vascular dementia (VD) in mice. The effects of bilateral common carotid artery stenosis (BCAS) on GPR30 expression at mRNA level were evaluated. Thereafter, the BCAS mouse model was utilized to evaluate the protection of Rg1 (0.1, 1, 10mg/kg, 14 days, ip). Spatial memory was evaluated by water Morris Maze 7 days post BCAS. After behavioral tests, neuronal apoptosis was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay, and potential mechanisms were determined using western blotting and quantitative real-time PCR. Our results showed that GPR30 expression in the hippocampal region at mRNA level was promoted 30min, 3h, 6h, and 24h following BCAS. Ginsenoside Rg1 (1 or 10mg/kg, 14 days, ip) promoted GPR30 expression in the hippocampus of model mice (after behavioral tests) but did not alter GPR30 expression in the hippocampus of control mice. Moreover, treatment of ginsenoside Rg1 (10mg/kg) or G1 (5μg/kg), a GPR30 agonist, prevented BCAS-induced memory impairment and hippocampal neuronal loss and apoptosis and promoted the ratio of Bcl-2 to Bax expression in the hippocampus (after behavioral tests). On the contrary, G15 (185μg/kg), an antagonist of GPR30, aggravated BCAS-induced hippocampal neuronal loss and apoptosis. Finally, drug-target molecular docking pointed that Rg1 had a lower binding energy with GPR30 compared with Bax and Bcl-2. Together, our data implicate that ginsenoside Rg1 prevents cognitive impairment and hippocampal neuronal apoptosis in VD mice, likely through promoting GPR30 expression. These results would provide important implications for the application of Rg1 in the treatment of VD.

28 September 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
KDKunrui Du
Kunrui Du
SYShaojie Yang
Shaojie Yang
JWJingji Wang
Jingji Wang
GZGuoqi Zhu
Guoqi Zhu
Cognitive impairment (CI) related to Alzheimer’s disease (AD) and vascular cognitive disorders (VCDs) has become a key problem worldwide. Importantly, CI is a neuropsychiatric abnormality mainly characterized by learning and memory impairments. The hippocampus is an important brain region controlling learning and memory. Recent studies have highlighted the effects of acupuncture on memory deficits in AD and VCDs. By reviewing the literature published on this topic in the past five years, the present study intends to summarize the effects of acupuncture on memory impairment in AD and VCDs. Focusing on hippocampal synaptic plasticity, we reviewed the mechanisms underlying the effects of acupuncture on memory impairments through regulation of synaptic proteins, AD characteristic proteins, intestinal microbiota, neuroinflammation, microRNA expression, orexin system, energy metabolism, etc., suggesting that hippocampal synaptic plasticity may be the common as well as the core link underlying the above mechanisms. We also discussed the potential strategies to improve the effect of acupuncture. Additionally, the effects of acupuncture on synaptic plasticity through the regulation of vascular–glia–neuron unit were further discussed.

2 August 2023 in Phytomedicine
Verified
Journal Article
Closed access
LCLixia Chen
Lixia Chen
YZYilan Zhen
Yilan Zhen
XWXuncui Wang
Xuncui Wang
JWJingji Wang
Jingji Wang
GZGuoqi Zhu
Guoqi Zhu

13 December 2024 in Experimental Neurology
Verified
Journal Article
Closed access
CLChang Liu
Chang Liu
XCXiaoyu Chen
Xiaoyu Chen
SYShaojie Yang
Shaojie Yang
XWXuncui Wang
Xuncui Wang
PSPeiyang Sun
Peiyang Sun
GZGuoqi Zhu
Guoqi Zhu